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In Brief
Brain repair through transplantation
shows great potential for the future
treatment of Parkinson’s disease. Aldrin-
Kirk et al. combine fetal transplants from
TH-Cre driver rats with bimodal
chemogenetic receptors to elucidate a
novel mechanism for graft-induced
dyskinesias.
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Transplantation of DA neurons is actively pursued as
a restorative therapy in Parkinson’s disease (PD).
Pioneering clinical trials using transplants of fetal
DA neuroblasts have given promising results,
although a number of patients have developed
graft-induced dyskinesias (GIDs), and the mecha-
nism underlying this troublesome side effect is still
unknown. Here we have used a new model where
the activity of the transplanted DA neurons can be
selectively modulated using a bimodal chemoge-
netic (DREADD) approach, allowing either enhance-
ment or reduction of the therapeutic effect. We
show that exclusive activation of a cAMP-linked
(Gs-coupled) DREADD or serotonin 5-HT6 receptor,
located on the grafted DA neurons, is sufficient to
induce GIDs. These findings establish a mechanistic
link between the 5-HT6 receptor, intracellular cAMP,
and GIDs in transplanted PD patients. This effect is
thought to be mediated through counteraction of
the D2 autoreceptor feedback inhibition, resulting in
a dysplastic DA release from the transplant.
INTRODUCTION
Restorative therapies based on nerve cell replacement, from
extrinsic or intrinsic sources, have seen significant advances
over the past decade. Interest in the therapeutic potential of
cell replacement in Parkinson’s disease (PD) in particular has
re-emerged with the new EU-funded clinical trial using fetal cells
(Abbott, 2014), the development of optimized and efficient differ-
entiation protocols for human embryonic stem cells (hESCs) (Kir-
keby et al., 2012; Kriks et al., 2011), and the emerging plans for
the use of hESCs or induced pluripotent stem cells (iPSCs) in
clinical trials in PD patients (http://www.gforce-pd.com/). Pio-
neering clinical trials, performed over the last decades usingNeuron 90, 955–968
This is an open access article unddopamine (DA) neuroblasts from fetal mesencephalon (still
considered the gold-standard DA cell replacement in PD) have
been encouraging but also raised significant concerns. While
some grafted patients have displayed substantial long-term clin-
ical benefit from the dopaminergic cell transplants placed in the
caudate/putamen (Kefalopoulou et al., 2014), the outcome has
been highly variable (Barker et al., 2013), and a significant num-
ber of patients have also developed abnormal involuntary move-
ments induced by the graft (graft-induced dyskinesias, or GID).
This troublesome side effect, seen in the absence of any drug
treatment, has so far not been possible to reproduce in rodent
or primate models of PD.
Recent studies have shown that these GIDs are dependent of
serotonergic neurotransmission (Politis et al., 2011) and that they
can be suppressed by drugs acting on inhibitory autoreceptors
located on the serotonin neurons (Politis et al., 2010). However,
the functional link between the serotonin system and dysregu-
lated DA neurotransmission causing dyskinesias still remains
elusive. The main reason for this is due to the fact that all at-
tempts to reproduce this side effect in an authentic and clinically
relevant animal model have so far failed.
The goal of this study was to explore the mechanism underly-
ing the induction of GIDs using a novel rat model where DA neu-
rons from Cre-expressing donor rats (a knockin Cre driver line
under the endogenous TH [tyrosine hydroxylase] promoter) are
transplanted to the striatum in parkinsonian rats. The transplants
are subsequently transduced to express, selectively within the
grafted DA neurons, a novel bimodal pair of chemogenetic re-
ceptors (designer receptors exclusively activated by designer
drugs, or DREADDs) (Vardy et al., 2015). While these DREADDs
have been shown to either increase or silence (depending on the
DREADD expressed) axonal firing in DA neurons in vivo and in
slice preparations (Mahler et al., 2014; Marchant et al., 2016;
Wang et al., 2013), this model enables us for the first time to
selectively regulate the activity of grafted DA neurons. This has
allowed us to unequivocally determine the functional impact of
ectopically transplanted DA neurons (placed in the striatum,
which is the target structure for dopaminergic transmission
from the A9 midbrain DA neurons and corresponds to the place-
ment in caudate/putamen in patients). While previous studies, June 1, 2016 ª 2016 The Authors. Published by Elsevier Inc. 955
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havemanaged to silence a tonically active hESC transplant using
optogenetic tools in mice (Steinbeck et al., 2015) or to activate
reprogrammed fibroblasts (mouse-derived induced neurons) us-
ing DREADDs in rats (Dell’Anno et al., 2014), this study aims to
achieve a selective and reversible bimodal regulation of the DA
neurons contained in the transplant, imperative to dissect the un-
derlying mechanisms of the GIDs.
In this study, we show that in vivo transduction of transplanted
Cre-expressing neurons using recombinant adeno-associated
viral (AAV) vectors carrying a Cre-inducible construct can be
achieved with very high efficiency and that this method can be
used to selectively regulate DA neuron function in a bimodal
manner. With this model, we demonstrate unequivocally that
an active DA neurotransmission is necessary for the therapeutic
capacity of the fetal graft. Our data also point to the fact that the
ectopic placement of the graft may result in a suboptimal func-
tion, and that this can be significantly enhanced using selective
activation of the DA cells in the graft.
We found that increase of cyclic AMP (cAMP) in the grafted DA
neurons, obtained through activation of the metabotropic Gs-
coupled DREADD (rM3Ds), is sufficient to induce significant
GIDs in animals in the absence of any L-DOPA treatment. Build-
ing on these findings, we were able to identify the serotonin
5-HT6 receptor as an important activator of DA neurons in the
graft and show that selective activation of this receptor using
the potent 5-HT6 agonist ST1936 can induce significant GIDs
with a phenotype very similar to L-DOPA-induced dyskinesias
(LIDs) even in unprimed animals (i.e., animals that never received
L-DOPA and thus never developed LIDs). Lastly, we show that
this receptor is highly relevant for clinical transplantation as post-
mortem analysis of human fetal cell transplants to the putamen
of PD patients shows expression of the receptor, as do human
DA neurons grafts obtained from human fetal brain or differenti-
ated hESCs.
RESULTS
Fetal Transplants from Knockin Cre Driver Rats
Reinnervate the Parkinsonian Striatum and Result in
Time-Dependent, Partial Recovery of Motor Function
The experimental setup of this study (Figure 1A) was designed
to allow for both the assessment of unperturbed therapeutic
capacity of fetal DA neuroblasts after transplantation (TX) and
for the assessment of chemogenetic activation (hM3Dq [Gq
coupled] and rM3Ds [Gs coupled]) and silencing (KORD [Gi
coupled]). The main activating DREADD combination, rM3Dq/
hM3Ds, was selected to enable drive of the DA neurons with a
simultaneous counteracting activity on the D2 autoreceptors.
The Gi-coupled D2 receptor reduces intracellular cAMP when
the synaptic DA concentration increases, with the result that
the activation threshold for further release is increased. The acti-
vation of the hM3Ds actively counteracts this effect. The novel
KORD receptor was matched with the hM3Dq to enable in vivo
studies of bimodal regulation where one ligand could induce
DA release (using CNO) and the other inhibit DA release (using
salvinorin B, or SalB). These two groups, together with the
rM3Ds/KORD group presented in Figure 6, enable us to compare
the action of Gs- and Gq-coupled G protein activation in DA neu-956 Neuron 90, 955–968, June 1, 2016rons. The DREADDs were specifically expressed in the mature
DA neurons of the transplant through the induction of gene tran-
scription using the Cre-loxP system. The Cre-recombinase was
selectively expressed in the DA neurons of the graft through
sourcing of TH-Cre ± fetal tissue from wild-type (WT) females
bred with male TH-Cre homozygous knockin rats. The specificity
of Cre expression was carefully examined in the adult TH-Cre rat
to confirm that the Cre expression is restricted to only DA neu-
rons in the ventral midbrain (Figures 1B, 1C, and S1B, available
online). Unilateral grafting of fetal dopaminergic neurons into the
striatum of 6-OHDA lesioned rats resulted in significant, yet par-
tial, recovery in the stepping and cylinder motor performance
tests (Figures 1D and 1E), as well as recovery in sensorimotor
neglect and the typical overcompensation in amphetamine-
induced rotations (Figures S1C and S1D). Selective expression
of transgenes in the grafted DA neurons was efficiently achieved
throughout the grafts using Cre-inducible AAV8 vectors injected
in the centroid between the 33 2 ml transplant deposits (Figures
1F and 1G). Quantification of TH-positive dopaminergic neurons
within the three graft tracts confirmed successful integration of a
large number of graft-derived DA neurons into the host tissue,
representing approximately 50% of the uninjured rat substantia
nigra (SN) (Figures 1F and 1H). Graft-derived, dopaminergic pro-
jections (assessed specifically using the Cre-activated HA-
tagged protein) were mainly localized to the striatum but were
also found in the cerebral cortex and in the reverse direction
along the medial forebrain bundle through the globus pallidus,
with projections reaching as far as the SN (Figures 1G and
S2A–S2E).
Fetal Transplants from Knockin Cre Driver Rats Allow
for Cell-Specific Targeting In Situ Using DIO-AAV8
Vectors
Chemogenetic modulation of neuronal activity of the graft-
derived TH neurons was achieved using three AAV8 vectors
delivering the activation and inhibiting DREADD constructs in
Cre-inducible (DIO, or double-floxed inverted orientation) ex-
pression cassettes. Histological analysis revealed that all three
graft deposits could be transduced with a single stereotactic in-
jection, achieving robust and highly specific transduction of TH-
positive neurons of all three transgenes (Figures 1G, 1I, 1J, and
S1E–S1L). The specificity and off-target function of this vector
were evaluated in vivo in the striatum of WT rats without Cre
expression (Figures 2A, 2B, S3A, and S3B) using both behavior
test and postmortem analyses to confirm that both the vectors
and the utilized ligands are biologically inert in the absence of
Cre (Figures 6B and 6C). Of note is that the expression strength
of the AAV-DIO-derived transgene does not correlate with TH
(and thereby Cre) expression as it is driven by the pan-neuronal
promoter Synapsin-1 and is strongly expressed also in DA neu-
rons with TH levels very near the detection limit (Figures 2C–2E
and S3C–S3H; Stuber et al., 2015). The following AAV8 DREADD
vectors were combined to allow for two types of bimodal regula-
tion: Gq- and Gs-coupled activation using the same activating
ligand (CNO, hM3Dq + rM3Ds, n = 11), or Gq-coupled activation
using the CNO ligand and Gi-coupled inhibition using the novel
orthogonal ligand SalB (hM3Dq + KORD, n = 13). In addition,
the Gs was evaluated without the Gq (rM3Ds + KORD, n = 6),
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Figure 1. Characterization of Dopaminergic Fetal Grafts and
AAV-Mediated Transduction Efficacy
(A) Experimental timeline illustrating the time points for all major surgical
procedures and behavioral tests for animals expressing hM3Dq/rM3Ds
and hM3Dq/KORD vectors.
(B and C) LSM of midbrain dopaminergic neurons, virally transduced
with AAV-8 DIO-mCherry and stained for TH (green) and mCherry (red).
VTA (B) and SN (C) dopaminergic neurons displayed high specificity for
mCherry-labeled neurons, demonstrating that the TH-Cre knockin rat
has highly selective expression of Cre recombinase, localized to
dopaminergic neurons.
(D and E)Motor recovery following grafting of dopaminergic fetal cells in
the stepping (D) and cylinder (E) behavior tests. Dashed line in graphs
represents the average performance of an unlesioned rat (see also
Figure S1). Lesioned animals receiving the fetal midbrain progenitor
transplants (TX) recovered significantly, yet not completely, in these
tests of advanced motor function, while there was no spontaneous
motor recovery observed in lesioned rats that were not transplanted
(Lesion Ctrl).
(F and G) Dark field microscopy imaging of three-site dopaminergic
grafts in horizontal sections, using DAB-amplified immunohistochem-
ical detection of the DA marker TH (F) and characterization of AAV
transduction efficacy using HA-tag antibody (detecting the tagged
hM3Dq transgene) (G) (see also Figure S2).
(H) Stereological quantification of dopaminergic neurons within the
grafts of both hM3Dq + rM3Ds (red) and hM3Dq + KORD (blue) trans-
duced animals in relation to intact midbrain dopaminergic neurons of
the SN pars compacta (dashed lines ± 1 SD).
(I) Quantification of AAV-transduced grafted neurons for the three
vector constructs: hM3Dq-HA-tag (blue), rM3Ds-mCherry (tan), and
KORD-GFP (cyan) for both groups of hM3Dq + rM3Ds and hM3Dq +
KORD transplants, presented as transduction efficiency related to the
number of TH+ transplanted DA neurons.
(J) LSM image of grafted neurons stained for rM3Ds-mCherry (red),
hM3Dq-HA (green), and TH (blue) (see also Figure S2).
Scale bar, 500 mm (G) and 100 mm (J). All values reported as arithmetic
mean ± 1 SEM. *p < 0.05 in Bonferroni corrected paired Student’s t test;
#significantly different from control (p < 0.05) in repeated-measures
ANOVA, followed by Bonferroni corrected one-way ANOVA, followed
by Dunnett’s T3 post hoc test.
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Figure 2. In Vivo Specificity Evaluation of
DIO-AAV Vectors to Transplanted TH-Cre-
Positive Neuroblasts and Off-Target In Vivo
Activation of the DREADD Ligands
(A and B) Expression of DIO-hM3Dq and DIO-
rM3Ds DREADDs, following viral infusion into the
striatum of WT animals (A) and animals grafted
with dopaminergic fetal tissue from TH-Cre
transgenic rats (B). *Denotes position of viral infu-
sion (see also Figure S3).
(C–E) Assessment of virally transduced, grafted
mCherry-positive neurons that appeared TH
negative under normal laser power conditions. (C)
Overview of dopaminergic fetal graft within the
striatum with an mCherry-positive neuron that
appeared TH negative (white box). When
comparing high-magnification z stacks of these
mCherry-positive grafted neurons under normal
laser power conditions (D) with high laser power
conditions (E), it is clear that these mCherry-posi-
tive (red) neurons are indeed TH positive (green),
although at low levels. We hypothesize based on
cell morphology and heterogeneous TH expres-
sion that these are grafted neurons originating
from the VTA (see also Figure S1).
(F) Control measurements in the intact striatum
using electrochemical chronoamperometric re-
cordings of DA release. Local KCl administration
(red arrow) evoked strong DA release while neither
CNO (blue arrow) nor SalB (black arrow) adminis-
tration resulted in any measurable increase in
extracellular DA.
Scale bar, 200 mm (B), 100 mm (C), and 10 mm (E).and a novel rat-codon-optimized, M4-based Gi DREADD was
developed (increasing sequence homology from 90% to
98.2%without changes in the amino acid sequence) and utilized
to evaluate the inhibitory function of the Gi on the function of the
graft (rM4Di + eYFP, n = 6) (Figure 6). Both ligands CNO and SalB
were confirmed to be otherwise biologically inert at the doses
administered (Figures 2F, 6B, 6C, and S6).
Chemogenetic Modulation of DA Grafts Using First and
Second Generation DREADDs Enables Functional
Potentiation and Silencing in the Same Animal
Local administration of CNO was able to produce a specific and
repeatable DA release from the transplants of a peak amplitude
similar to that of KCl (as measured by in vivo electrochemical
detection methods) in animals receiving both vector mixes,
but with slower reuptake rate (Figures 3A, 5D, S6B, and S6F).
In animals receiving the hM3Dq + KORD combination, local
administration of SalB 60 s before KCl injection could strongly
suppress the KCl-induced DA release (Figures S6D and S6H).
The inhibition was also rapid enough to preemptively terminate
the Gq-mediated release, demonstrating in vivo bidirectional
modulation (Figure 3B). Of note is that the recording of the DA958 Neuron 90, 955–968, June 1, 2016release was performed at the centroid between the transplant
deposits very close to the site of AAV injection to ensure that
the release from terminals is recorded and that the highest frac-
tion of transplanted DA neurons is transduced at the site of
recording; i.e., a higher transduction rate is expected at the
site of recording than that presented in Figure 1I.
After systemic CNO administration, animals expressing the
hM3Dq + rM3Ds combination displayed significantly improved
motor performance in both the cylinder task and the stepping
test in response to CNO, with some animals returning to prele-
sion levels (Figures 3D and 3F). In contrast, graft-induced recov-
ery in these tests was abolished in animals with transduced
hM3Dq + KORD grafts, following treatment with SalB, suppress-
ing the therapeutic effect of the transplant entirely in the cylinder
test and to a significant portion in the stepping test (Figures 3C
and 3E), but not in the corridor test (Figures 3G and S4A).
Interestingly, CNO treatment was sufficient to increase the
performance in a complex sensorimotor integrative task, the
disengage task that is earlier known to be only marginally
improved by DA neuron grafts (Mandel et al., 1990; Winkler
et al., 2000) (Figures 3H and S4B). The therapeutic effect was
measured as decreased response latency and was observed
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Figure 3. Bidirectional Modulation of DA Release from
Grafted Neurons Using DREADDs
(A) Chronoamperometric in vivo recordings in the striatum (in prox-
imity to the transplantation sites), comparing DA release following
local administration of KCl (red) and CNO (blue) from the dopami-
nergic graft. The average peak DA concentration after CNO (1.08 ±
0.51 mM) was comparable to the average KCl-induced DA release
(1.60 ± 0.41 mM).
(B) In vivo recordings of bidirectional DA modulation from hM3Dq +
KORD-expressing graft where CNO (blue arrow)-induced DA
release could be silenced following administration of SalB at
assumed peak of release (black arrow). The average peak DA con-
centration on CNO was 1.49 ± 0.20 mM compared to 0.67 ± 0.11 mM
when combined with inhibition of the graft using SalB.
(C and D) Systemic, noninvasive modulation of the dopaminergic
graft during assessment in the cylinder task comparing unmodu-
lated graft baseline (tan) to lesion baseline (cyan) and 15 min
following SalB treatment (blue). Inhibition of function occurred in
hM3Dq + KORD animals, but not in animals lacking the KORD re-
ceptor (C), while CNO treatment (green) significantly increased
motor performance in hM3Dq + rM3Ds animals (D).
(E and F) Bidirectional modulation of motor behavior in the stepping
task with hM3Dq + KORD animals reducing motor recovery
following SalB treatment (E) and increasingmotor recovery following
CNO treatment (F), while the ameliorating effect of the hM3Dq +
rM3Ds transplants could be increased by treatment with CNO (F)
and remained unaltered after SalB administration (E).
(G and H) Sensorimotor performance in response to treatment with
SalB and CNO in the corridor task (G), and therapeutic potentiation
after CNO in a complex sensorimotor integrative task, measured as
the decrease in response latency in the disengage test (H) (see also
Figure S3).
All values reported as arithmetic mean ± 1 SEM. *p < 0.05 in Bon-
ferroni corrected paired Student’s t test; xp< 0.05 in two-waymixed-
model ANOVA followed by Tukey’s post hoc.
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Figure 4. GIDs in Animals with CNO-Acti-
vated hM3Dq + rM3Ds Receptors in the DA
Transplant
(A) Rotational asymmetry was prominent when
activating the DA neurons in the transplant of
hM3Dq + rM3Ds animals with CNO, but not
hM3Dq + KORD or Lesion Ctrls.
(B) Rotational behavior induced by apomorphine,
however, showed a strong contralateral rotation in
Lesion Ctrl animals (red), which was comparatively
reduced in grafted hM3Dq + rM3Ds (blue) and
hM3Dq + KORD (green) animals, indicating a
reduced postsynaptic DA receptor supersensiti-
vity, normalized by the graft.
(C) When observed in a home-cage-like environ-
ment, treatment with CNO induced AIMs in the
hM3Dq + rM3Ds animals only.
(D) Apomorphine injections, on the other hand,
induced strong AIMs in Lesion Ctrl animals, which
was significantly reduced in grafted hM3Dq +
rM3Ds and hM3Dq + KORD animals.
All values reported as arithmetic mean ± 1 SEM.
*AUC (area under the curve) significantly different
from the Lesion Ctrl group, #AUC significantly
different from both treatment groups, p < 0.05
using one-way ANOVA followed by Dunnett’s T3
post hoc. xAUC significantly different from all other
groups, p < 0.05 using one-way ANOVA followed
by Tukey’s post hoc.in both hM3Dq + rM3Ds and hM3Dq + KORD animals after CNO
administration.
Increases in cAMP in DA Neurons of the Graft
Selectively Modulate Involuntary Movements
During the acquisition of the behavior modulation data after
CNO administration, hM3Dq + rM3Ds animals were observed
to exhibit abnormal body posture, rotational locomotion, and
spontaneous limb activity at the peak dose of CNO. hM3Dq +
rM3Ds, but not hM3Dq + KORD, animals were found to display
a significant and dose-dependent rotational bias away from
the transplanted hemisphere (contralateral rotation) in response
to CNO (Figures 4A and S4C). When observed in an uncon-
strained home-cage environment, the same treatment group
displayed a broader spectrum of abnormal involuntary move-
ments (AIMs), including both axial and orolingual repetitive
movements, peaking around 60 min following CNO treatment
and lasting for longer than 2 hr (Figures 4C and 5C; Movie S1).
Interestingly, neither the hM3Dq + KORD animals nor the lesion
control animals developed any rotational behavior or AIMs in
response to CNO. Thus, increase in cAMP, the principle intracel-
lular activation mechanism of Gs-coupled G protein receptors,
may be a critical mechanism behind GIDs. Indeed, when acti-
vating the graft by CNO-induced increase of cAMP using the960 Neuron 90, 955–968, June 1, 2016rM3Ds DREADD alone, the rotational
asymmetrywas found to the samemagni-
tude (Figure 6D).
To confirm that these findings were
indeed due to presynaptic dysregulation
and not postsynaptic receptor sensitivity,animals were treated with the DA agonist apomorphine. While
the lesion control animals remained highly supersensitized to
apomorphine in the ipsilateral striatum, both hM3Dq + rM3Ds
and hM3Dq + KORD displayed significantly reduced rotational
behavior and AIMs, consistent with graft-mediated reduction of
postsynaptic receptor sensitivity (Figures 4B and 4D).
Selective Activation of the 5-HT6 Receptor Is Sufficient
to Induce GIDs
As noted above, both clinical and preclinical evidence point to
the serotonergic neurotransmission as an upstream event
required for the maintenance of GIDs. However, the mechanism
through which this activation is inducing dysplastic events via
the graft remains elusive. Three of the seven families of seroto-
nergic (5-HT) receptors present in the CNS are metabotropic
and signal through the Gs cascade: 5-HT4, 5-HT6, and 5-HT7.
Therefore, selective agonists toward these receptors were eval-
uated in the hM3Dq + KORD-treated animals, as they had yet to
show any rotational asymmetry or AIMs. While the 5-HT4
(BIMU8) and 5-HT7 (AS19) agonist did not induce any rotational
asymmetry, the selective 5HT-6 agonist ST-1936 induced both
contralateral rotational behavior as well as AIMs very similar to
that observed following CNO treatment (Figures 5A and 5B).
Electrochemical recordings of DA release in vivo in response to
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Figure 5. Treatment with 5-HT6 Agonist ST-
1936 Induces DA Release and GIDs through
Direct Action on the Grafted DA Neurons
(A) Rotational behavior following treatment of 5-HT
agonists specifically targeting each of the three
metabotropic, Gs-coupled, serotonin (5-HT) re-
ceptors, with 5-HT4 agonist BIMU8 (green) and
5-HT7 agonist AS19 (black) not inducing any rota-
tional behavior, while 5-HT6 agonist ST-1936 (blue)
induced a strong contralateral rotation in grafted
hM3Dq + KORD animals (L-DOPA naive and not
previously displaying GIDs on CNO), but not Lesion
Ctrls (red).
(B) Treatment with 5-HT6 agonist ST-1936 induced
substantial AIMs in grafted hM3Dq + KORD ani-
mals (green) with only a weak, transient AIM score
in Lesion Ctrls (red).
(C) Comparison of the different manifestations of
AIMs between treatments with CNO, apomorphine,
and ST-1936. CNO induced mainly locomotor
(blue), axial (green), and orolingual (purple) AIMs in
hM3Dq + rM3Ds animals. Grafted animals dis-
played a marked reduction in AIMs following
treatment with apomorphine, with limb AIMs (red)
being abolished. AIMs following treatment with ST-
1936 induced mainly orolingual and axial AIMs,
with a relatively small proportion of limb and loco-
motor AIMs in hM3Dq + KORD-grafted animals. In
contrast, Lesion Ctrls mainly exhibited locomotor
AIMs with a very small proportion of AIMs being
orolingual.
(D–G) Electrochemical recordings of DA release
in response to local ligand administration, with
CNO (D) and ST-1936 (E) inducing a prolonged
DA release with very similar kinetics in hM3Dq +
KORD-grafted animals, while both KCl (F)
and ST-1936 (G) induced a short spike of
DA with very different kinetics when applied
in the intact, nongrafted striatum (see also
Figure S6).
(H) LSM image showing strong expression of
5-HT6 (red) colocalized with virally transduced
(green) TH (blue)-positive neurons within the
dopaminergic fetal graft.
(I–L) Magnified z stack of a dopaminergic neuron
(taken from dashed square in H) showing the co-
localization between virally transduced KORD
expression (I), 5-HT6 (J), and TH (K) together with
an overlay composite (L) (see also Figure S5).
All values reported as arithmetic mean ± 1 SEM. *AUC significantly different from the Lesion Ctrl group, p < 0.05 using Kruskal-Wallis test followed by Bonferroni
corrected all-pair comparison, using the Mann-Whitney U test in (A) and using Student’s t test in (B). Scale bar, 100 mm (H) and 10 mm (L).locally administered ST-1936 revealed a strong release of DA
from the transplant with release kinetics strikingly similar to those
evoked by the local CNO release with an initial fast response, fol-
lowed by a slow, gradual reduction in DA levels, indicating that
DA release evoked by CNO and ST-1936 may be due to a similar
mechanism (Figures 5D and 5E). The other 5-HT agonists,
BIMU8 and AS19, did not induce DA release upon local admin-
istration in the transplant or in the intact striatum at the highest
concentrations used (100 mM) (data not shown). Although locally
administered ST-1936 to the intact, nongrafted striatum did
evoke DA release, the release pattern of DA was drastically
different, with a fast spike of DA that quickly returned to baselinelevels, very similar to that of local KCl administration (Figures 5F,
5G, and S6J). In order to confirm that the mechanism of action
from ST-1936 is mediated through the DA neurons of the trans-
plant, the rotational asymmetry was re-evaluated in a transplant
group receiving the de novo-generated inhibitory DREADD
rM4Di, which confers an inhibition of neuronal activity much
longer than the KORD. In these animals, we found that the
ST-1936-induced rotation could be abolished through pretreat-
ment with CNO (Figure 6E). To confirm that the 5-HT6 agonist
could act directly on the grafted DA neurons, brain sections
from grafted animals were triple-stained for 5-HT6 receptor,
TH, and a Cre-inducedmarked (GFP). A subgroup of TH-positiveNeuron 90, 955–968, June 1, 2016 961
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Figure 6. Second Experimental Group: Vali-
dation of the rM3Ds DREADD and Reversal
of the 5-HT6-Induced Involuntary Move-
ments by rM4Di DREADD
(A) Experimental timeline illustrating the time points
for all major surgical procedures and behavioral
tests for animals expressing rM3Ds/KORD and
rM4Di/eYFP vectors.
(B and C) Noninvasive modulation of the dopami-
nergic fetal graft during assessment in the stepping
and cylinder tasks, comparing unmodulated lesion
baseline (cyan) to graft baseline (tan) and 1 hr
following CNO treatment (green).
(B) Comparison between grafted rM3Ds/KORD-
and rM4Di/eYFP-expressing animals, as well as
nongrafted hM3Dq/rM3Ds transduced controls
and nongrafted, nontransduced controls. rM3Ds
receptor alone significantly potentiates motor
performance in response to CNO treatment, while
inert in hM3Dq/rM3Ds nongrafted animals. Inhibi-
tion of motor function occurred in animals ex-
pressing hM4Di in response to CNO in the step-
ping task.
(C) Comparison between grafted rM3Ds/KORD
and hM3Dq/rM3Ds transduced nongrafted con-
trols in the cylinder task.
(D) Rotational behavior in response to CNO
(10 mg/kg) in grafted rM3Gs/KORD animals com-
pared to hM3Dq/rM3Ds transduced nongrafted
controls.
(E) Rotational behavior in response to 5-HT6
agonist ST-1936 (20 mg/kg) in grafted animals and
inhibition of this behavior by the CNO-dependent
hM4Di DREADD. CNO treatment effectively abol-
ished ST-1936-mediated rotational behavior, sug-
gesting that 5-HT6-mediated rotational behavior in
grafted animals is DA dependent.
All values reported as arithmetic mean ± 1 SEM.
*AUC significantly different from the Lesion
Ctrl group, p < 0.05 using Student’s t test, #AUC
significantly different from both TH-Cre TX
rM4Di+eYFP +ST1936 +CNO and Lesion Ctrl WT
hM3Dq+rM3Ds +ST1936, p < 0.05 using one-way
ANOVA followed by Dunnett’s T3 post hoc.neurons was observed that stained strongly positive for the
5-HT6 receptor. These cells were mainly of a smaller rounded
morphology but were present all through the graft (Figures 5H–
5L and S5A–S5D). Midbrain dopaminergic neurons on the nonle-
sioned side of these animals did also stain positively for the
5HT-6 receptor, although at a much lower level and with more
diffuse staining pattern (Figures S5E–S5H).
Previous studies have reported that transplants derived from
fetal ventral mesencephalon (VM) can contain variable numbers962 Neuron 90, 955–968, June 1, 2016of 5-HT neurons (Carlsson et al., 2007) and
that 5-HT hyperinnervation of the trans-
planted striatum may contribute to GIDs
(Politis et al., 2010). Using high-resolution
confocal microscopy, we also found that
5-HT transporter (SERT)-positive neurons
indeed exist in the transplant and that
both the transplant and the host striatumare densely innervated by 5-HT projections (Figures 7A–7D). At
no time was the SERT found in TH-positive cells of the trans-
plant, confirming that these are two distinct populations.
Furthermore, the SERT-positive projections densely contacted
the transplanted DA neurons with a large number of SERT-pos-
itive varicosities touching the DA cell soma, further suggesting
that there is a likely environment inside the graft for serotonergic
neurotransmission to be a regulator of DA neuron activity acting
though the 5-HT6 receptor (Figure 7E).
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Figure 7. Host- and Graft-Derived Serotonin Neurons Densely Inner-
vate the DA Neurons of the Transplant
(A–D) Overview immunofluorescence staining of serotonin expression in the
striatum of animals that received dopaminergic fetal grafts, using LSM, stained
for (A) SERT, (B) TH, and (C) DAPI with an overlay composite (D). Serotonin
projections were as expected—abundant in the striatum with SERT-positive
projections infiltrating the grafted tissue.
(E) High-magnification z stack of grafted dopaminergic neuron (red) in close
proximity to infiltrating SERT-positive (green) projections (white arrows).
SERT-positive projections were found to be within close range around grafted
dopaminergic neurons, suggesting communication between the two.
Scale bars, 100 mm (A) and 10 mm (E).The 5-HT6 Receptor Is Also Strongly Expressed in DA-
Neuron-Rich Grafts When Transplanted to the Human
Brain
Very little data exist on the expression of the 5-HT6 receptor in
DA neurons, especially of human origin. This is of paramount
importance, as to date, spontaneous GIDs have only been
observed after transplantation of human fetal VM tissue to the
human brain. In this experiment, we first utilized human fetal tis-
sue, obtained from 5- to 8-week-old elective terminations of
pregnancies wherefrom the dissociated VM was transplanted
to the DA-depleted striatum of immunosuppressed rats. When
sacrificed 8 weeks post-transplantation, the TH+ cells of this
transplant displayed a very strong expression of the 5-HT6 re-
ceptor (Figures 8A–8E). A small open label proof-of-concept clin-
ical trial utilizing fetal VM transplantation to the putamen of PD
patients has been performed in Lund, Sweden, with a number
of patients experiencing good symptomatic relief (Piccini et al.,
1999), but some patients also developed GIDs (Hagell et al.,
2002). The brain from one of these patients with a functional
graft, who died from other causes 24 years post-transplantation,
was harvested for histological analysis. In this brain, we found
that the 5-HT6 receptor was very highly expressed inside the
TH+ neurons to amuch higher extent than found in the host stria-
tum or in other transplanted neurons (Figures 8F–8J).With recent
advancements in the differentiation protocols of hESCs into
transplantable DA neuroblasts that now approach the fetal-tis-
sue-derived equivalents (Grealish et al., 2014), clinical trials are
being envisioned utilizing this cell source in PD. Thus, we evalu-
ated the 5-HT6 expression in transplants originating from the H9
hESC line, differentiated using the novel floor-plate-based proto-
col (Kirkeby et al., 2012; Kriks et al., 2011) and transplanted into
the striatum of immune-compromised nude rats. Also in this
case, the 5-HT6 receptor was highly expressed in the hESCs
that successfully differentiated into TH+ neurons, but not in
any other cells originating from the human transplant or the
host striatum (Figures 8K–8O). Together, these data point to
the fact that the 5-HT6 receptormay also be important in the clin-
ical setting and that it is not exclusive to fetal-derived DA neu-
rons, but that it is also highly relevant when planning transplan-
tation trials using hESC-derived DA neurons.
DISCUSSION
Cell transplantation has a unique capacity to restore degener-
ated neural circuitry. To date, this is a capacity that no alternative
therapy in PD (e.g., gene therapy) possesses. However, func-
tional regulation and the issues of GIDs still raise concerns for
future clinical trials. In this study, we have for the first time
been able to generate a rat model where DA neurons derived
from fetal midbrain neuroblasts can be selectively modulated us-
ing a bimodal chemogenetic approach. The use of a novel
knockin Cre driver line as the source of the DA grafts ensured
the selectivity to DA neurons of this regulation. This is, to our
knowledge, the first time that cell-type-specific modulation of
graft activity is achieved in vivo. Previous studies utilizing opto-
genetics or DREADDs in hESC- and inducible neuron (iN)-
derived transplants, respectively, have both relied on in vitro
transduction utilizing pan-neuronal expression of the regulatingNeuron 90, 955–968, June 1, 2016 963
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Figure 8. The 5-HT6 Receptor Is Highly Ex-
pressed in Human Tissue Grafts Originating
from Both Fetal and hESC Sources
(A–E) Immunofluorescence staining of 5-HT6
expression in a human dopaminergic fetal graft
within the rat striatum (A and C) with the pheno-
typic staining for TH (A and B), and the identifica-
tion of humanNCAM (A andD), imaged using LSM.
The 5-HT6 expression was confirmed to reside in
DA neurons originating from the transplanted tis-
sue (E).
(F–J) Similarly, immunofluorescence staining of
a paraffin-embedded section originating from
the putamen of a PD patient that received a
dopaminergic fetal graft, imaged using LSM,
confirmed that the 5-HT6 receptor (F and H) is
highly expressed in the TH-positive (F and G, with
overlay in J) DA neurons originating from the
fetal graft. Nuclear staining (DAPI) confirmed the
5-HT6 expression to be abundant in the neuronal
soma (I).
(K–O) To confirm if this receptor is also abundant in
DA neurons differentiated from hESCs, a graft
derived from the H9 hESC line, differentiated using
the novel floor-plate-based protocol and trans-
planted to the parkinsonian striatum of a nude rat,
was evaluated using LSM with immunofluores-
cence for the same genes: 5-HT6 (K and M), TH (K
and L), and the human NCAM (K and N). This
confirmed that this receptor is highly expressed
in DA neurons also differentiated from this cell
source, when transplanted to the striatum. Overlay
of all three antigens confirmed the 5-HT6 receptor
to reside in hESC-derived DA neurons (O). Scale
bar, 100 mm (K) and 50 mm (N).genes (Dell’Anno et al., 2014; Steinbeck et al., 2015). This is an
important technical advancement that makes it possible to
dissect the functional contribution of DA neurons contained in
the graft, as both fetal and hESC-derived DA transplants contain
a broad diversity of both neuronal and nonneuronal cells (Kriks
et al., 2011; Thompson et al., 2008).
Using this novel approach, we have been able to make three
important discoveries. First, our results show that the ectopic
placement of the transplant, i.e., in striatum rather than in the
normal location in the SN, while providing significant symptom-
atic relief, does not recall the full potential of the grafted DA neu-
rons. Through selective activation using chemogenetic receptor964 Neuron 90, 955–968, June 1, 2016stimulation, the therapeutic potential of
these transplants was significantly poten-
tiated, providing near-complete recovery
in tests of both simple and complex
sensorimotor integrative behavior, a level
of improvement not reached under base-
line conditions. Notably, the functional
improvement we observed here following
activation of the DA neurons through the
cAMP-linked Gs pathway is far greater
than has been reported by chemogenetic
techniques previously (and no successful
activation of transplanted DA neurons us-ing optogenetics has been reported to date) (Dell’Anno et al.,
2014). The improvement reported by Dell’Anno from the
mouse-fibroblast-derived iDA neurons activated through the
Gq pathway was very subtle and similar to the magnitude we
observed in the hM3Dq + KORD group (Dell’Anno et al., 2014).
Furthermore, we were able to demonstrate that the lesion-
induced behavioral deficit is ameliorated by the transplant itself
and not through any possible secondary effects. Thus, the
reversible inhibition obtained using SalB (in the Gq + KORD
rats) reinstated the behavioral deficits in the stepping and cylin-
der tests. Similar functional reversal has been observed previ-
ously when either the entire transplant was physically removed
(Bjo¨rklund et al., 1980) or when the DA neurons of the transplants
were selectively killed through injection of 6-OHDA into the graft
(Dunnett et al., 1988). A previous report has used optical inhibi-
tion of all neurons of the hESC transplant to reinstate a deficit
on the corridor test (Steinbeck et al., 2015), but this is the first
time that the reversal of motor recovery is achieved through tran-
sient silencing of only the transplant-derived DA neurons.
Second, we show that exclusive activation of the DA neurons
in the graft through cAMP-linked (Gs-coupled) receptor activa-
tion is sufficient to induce GIDs in non-L-DOPA primed parkinso-
nian rats. While earlier preclinical studies have induced AIMs in
DA-grafted, L-DOPA primed rats using d-amphetamine to
induce strong release of both serotonin and DA from the host
and graft (Lane et al., 2006; Shin et al., 2012), we here for the first
time present a GID model that is only dependent on activation of
the transplanted DA neurons. Through a comparison of the DA
release induced via hM3Dq to that induced via hM3Ds, we could
show for the first time that it is not the magnitude of DA release
(release amplitude was similar in both cases), but it is the release
kinetics that drive the abnormal involuntary movements. More-
over, and in line with previous observations (Carlsson et al.,
2007; Lane and Winkler, 2012), the response to apomorphine
in the AIMs and rotation tests was markedly reduced in the
transplanted groups (Figures 4B and 4D), indicating that
the appearance of GIDs is not due to postsynaptic receptor
sensitization.
Third, we show that activation of the cAMP-linked, 5-HT6 re-
ceptor, expressed on the grafted DA neurons, induces a strong
and prolonged DA release in the reinnervated host striatum,
and that this stimulation is also sufficient to induce rotational
asymmetry and GIDs in the transplanted animals, pointing to a
key role of this specific serotonin receptor in the induction of
GID. These data point to DA as a key player in the induction of
GIDs. Here, we have a unique modulation capacity of DA and
have shown that very efficient DA release in itself, as achieved
by the hM3Dq DREADD construct, is not sufficient to induce
GIDs. The dysplastic DA release as achieved by the rM3Ds is,
however, sufficient to induce involuntary movements, both alone
and in combination with the hM3Dq DREADD. These findings
point to an interesting supersensitivity in grafted DA neurons to
changes in cAMP compared to the endogenous nigral DA neu-
rons. This is observed both as a more prolonged DA peak in
the in vivo electrochemical recordings and in the dramatically
different behavioral changes in response to the 5-HT6 agonist
in the grafted animals as compared to the lesioned controls. It
is known that activation of the D2 autoreceptor reduces DA
release probability through a decrease in cAMP (Weiss et al.,
1985). This raises the possibility that the increase in cAMP levels
induced by 5-HT6 activation blocks this autoregulatory mecha-
nism in the supersensitive grafted DA neurons, but not in the
endogenous DA neurons, resulting in an increased synaptic DA
concentration in the transplanted striatum. It is worth noting
that there are a number of other receptor subtypes that also
regulate cAMP, e.g., muscarinic acetylcholine and adenosine re-
ceptors thatmay also contribute toGIDs. However, we have here
shown that 5-HT6 activation alone is sufficient to induce GIDs.
Through the studies of the unique patient material and the
human-derived tissue transplanted to immune-compromisedrats, we have here for the first time shown that the 5-HT6 recep-
tor is highly expressed in transplanted DA neurons and also in
transplanted PD patients.
These data are very much in line with the clinical observations
by Politis et al. (Politis et al., 2010, 2011). Using PET imaging with
the 5-HT transporter imaging ligand 11C-DASB, they propose
that serotonergic hyperinnervation derived from serotonin neu-
rons contained in the graft is a key contributing factor to GIDs,
and they show that silencing of the 5-HT system, using an
agonist of the inhibitory 5-HT1A autoreceptor, Buspirone, is
efficient in dampening GIDs in grafted patients. These observa-
tions point to a GID-inducing signaling cascade where sero-
tonin released from 5-HT terminals acts on the 5-HT6 receptor
of cAMP hypersensitive transplanted DA neurons to induce
involuntary movements. The clinical relevance of this sig-
naling cascade is further supported by the observation that the
5-HT6 receptor is markedly upregulated in transplanted human
midbrain DA neurons, as observed in material obtained from a
grafted PD patient, as well as in transplants of human fetal VM
tissue and hESC-derived DA neurons transplanted to immune-
compromised rats.
This study provides, for the first time, a mechanism through
which serotonergic neurotransmission can induce GIDs in
grafted PD patients. In patients receiving transplants of fetal
VM tissue, the serotonin hyperinnervation caused by 5-HT neu-
rons included in the graft tissue preparation is likely to play an
important role. This mechanistic finding should open up more
efficient and focused strategies to ameliorate or avoid GIDs in
future clinical trials utilizing cell replacement strategies in PD
without reducing the therapeutic potential. In addition, our study
provides the first demonstration that a combination of chemoge-
netic receptors can be used as a tool for bimodal regulation of
transplanted neurons. This approach may be used clinically to
enable fine-tuning of graft activity and thus a more refined
approach to restorative therapy, as well as opening up novel
routes to investigate the contribution of a transplant to behav-
ioral recovery.
EXPERIMENTAL PROCEDURES
To evaluate modulatory efficacy of DREADDs in dopaminergic fetal grafts, WT
rats (n = 62) received unilateral 6-OHDA lesions to the medial forebrain bundle
(MFB), followed by striatal grafting of dopaminergic precursor cells obtained
from the VM of TH-Cre rat embryos (n = 38). This was followed by a stereotac-
tic, intraparenchymal injection of an AAV-8 vector containing constructs ex-
pressing either hM3Dq + KORD (n = 13), hM3Dq + rM3Ds (n = 12), rM3Ds +
KORD (n = 6), or hM4Di + eYFP (n = 6). Two groups of 6-OHDA lesioned ani-
mals that did not receive dopaminergic fetal grafts received either no viral vec-
tors (n = 4) or were injected with hM3Dq + rM3Ds viral vectors (n = 4) and used
as controls. All animals were evaluated for motor and sensory impairment us-
ing a wide array of behavioral tasks. Most hM3Dq + KORD and hM3Dq +
rM3Gs animals were sacrificed 18–32 weeks postgrafting, directly following
in vivo electrochemical recording, while rM3Ds +KORD and hM4Di + eYFP an-
imals were sacrificed at 40 weeks postgrafting of fetal dopaminergic neurons.
Postmortem analysis focused on evaluating surviving dopaminergic neurons
within the striatum as well as receptor coexpression in the transplanted cells
using immunohistochemistry.
Animal Research
Adult female Sprague-Dawley rats (225–250 g) were housed in standard
laboratory cages with ad libitum access to food and water, under a 12:12 hrNeuron 90, 955–968, June 1, 2016 965
dark-light cycle in temperature-controlled rooms. All experimental procedures
performed in this study were approved by the regional ethics committee.
AAV Vectors
DIO-AAV-8 vectors containing the hSyn-rM3Ds-mCherry, hSyn-hM3Dq-HA,
hSyn-KORD-IRES-mCitrine, and hSyn-eYFP constructs, flanked 30 by the
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE),
were produced by transient transfection in HEK293 cells. Viral titers were
determined to range between 4E12 and 1.2E13 using qPCR.
Preparation of Dopaminergic Fetal Cells
Embryonic day 13.5 TH-Cre heterozygous embryos were removed from the
amniotic sac, and the VM from each embryo was carefully dissected and
pooled together in ice-cold DMEM/F12 media. Tissue pieces were then incu-
bated with 0.1% trypsin and 0.05% DNase in HBSS for 20 min at 37C and
subsequently mechanically dissociated and engrafted into the striatum of
6-OHDA lesioned WT Sprague-Dawley rats (33 2 mL deposits of 4.6E4 viable
cells/ml, a total of 275,000 cells).
Preparation of Mesencephalic DA hESCs
Differentiation of H9 hESCs (WA09, passage 21–45) into dopaminergic progen-
itors was done as described previously (Kirkeby et al., 2012). Cells were en-
grafted into 6-OHDA lesioned SD rats using a microtransplantation approach
in 23 1 mL deposits of 75,000 cells/mL (total of 150,000 cells). Immunosuppres-
sive treatment was administered in the form of daily intraperitoneal (i.p.) injec-
tions of cylosporine A (10 mg/kg) beginning 1 day before transplantation.
Preparation of Primary Human Ventral Midbrain
Human fetal tissuewas obtained from 5- to 8-week-old elective terminations of
pregnancies and collected with approval of the Swedish national board of
health and welfare and in accordance with local ethical guidelines and under
informed consent from the donors. Dissection and preparation of the tissue
were done as described previously (Bjo¨rklund et al., 1983; Rath et al., 2013).
Fetal tissue was prepared in a semicrude suspension and engrafted into
6-OHDA lesioned SD rats.
Postmortem Tissue from PD Patient Receiving Fetal Transplant
The preparation of fetal tissue, surgical procedures, and clinical outcome of
this patient have been described in detail previously (Hagell et al., 2002; Lind-
vall et al., 1992; Piccini et al., 1999). Shortly after death, the brain tissue was
prepared for specific analyses within the frames of the post-transplantation
follow-up study following procedures approved by the Regional Ethical Re-
view Board in Lund. The brain was removed and fixed in 6% buffered formal-
dehyde solution for 2 months. The basal ganglia were paraffin embedded for
subsequent sectioning into 4 mm thick sections.
Stereotaxic Surgery
Deeply anesthetized rats received a small burr hole through the skull, and the
solution containing either 6-OHDA, fetal progenitor cells, or viral vectors was
infused unilaterally into the brain using a pulled glass capillary attached to a
25 mL Hamilton syringe. The following coordinates and volumes were utilized:
MFB lesion, 3 mL of 6-OHDA at AP = 4.4, ML = 1.1, and DV 7.8 with
infusion rate of 0.3 mL/min (Figure S1A). For DA grafting, 33 2 mL at three sites
(defined as mm from bregma in AP andML and from dura in DV): (1) AP = +1.8,
ML = 2.5, and DV = 4.5; (2) AP = +0.6, ML = 2.0, and DV = 4.5; and (3)
AP = +0.6, ML = 3.2, and DV = 4.5, with an infusion rate of 0.4 mL/min. For
AAV-8 viral vectors injected into the striatum: 3 mL in the center of the three
grafts with two deposits, AP = +1.0, ML = 2.6, and DV = 4.5 and 3.5,
with an infusion rate of 0.4 mL/min.
Tissue Preparation and Immunohistochemistry
Rat brains were fixed in situ using transcardial perfusion of 4% paraformalde-
hyde (pH 7.4) in 0.1M phosphate buffer and cryoprotected in buffered sucrose
(25%). They were then cut into coronal or axial sections with a thickness of
35 mm and 45 mm, respectively. Human tissue from grafted putamen was fixed
postmortem in 6% formalin for 1 month and then embedded in paraffin.
Paraffin-embedded tissue was then cut into 4 mm thick coronal sections.966 Neuron 90, 955–968, June 1, 2016Using a standard free-floating immunohistochemistry protocol, the following
antibodies were utilized: anti-TH (Millipore, Cat #AB152, RRID: AB_390204,
1:1,000), anti-5-HT6 (Novus, Cat #NBP1-46557, RRID: AB_10009833,
1:1,000), anti 5-HT6 (Santa Cruz, Cat #sc-26668, RRID: AB_2280074,
1:1,000), anti-SERT (Millipore, Cat #MAB1564, RRID: AB_94220, 1:1,000),
anti-human-NCAM (Santa Cruz, Cat #sc-106, RRID: AB_627128, 1:1,000),
anti-HA-tag (Covance, Cat #MMS-101R-200, RRID: AB_10064220, 1:2,000),
anti-mCherry (LifeSpan Biosciences, Cat #LS-C204207, 1:1,000), and anti-
GFP (Abcam, Cat #ab13970, RRID: AB_300798, 1:20,000). Biotinylated sec-
ondary antibodies were utilized for DAB immunohistochemistry and amplified
by Vectorlabs ABC kit. For immunofluorescence, Alexa-conjugated secondary
antibodies were utilized.
Behavior Tests
Rotational locomotion was quantified in automated rotometer bowls (AccuS-
can Instruments, Inc.), where the rats were allowed to habituate in the
rotometer for 10 min prior to drug injection. As described in Figure 1A, the an-
imals’ rotational behavior was quantified after injection of d-amphetamine
(2.5 mg/kg, i.p.), apomorphine (0.05 mg/kg, subcutaneously [s.c.]), CNO (3
or 10 mg/kg, s.c.), and 5-HT receptor agonists (5–20 mg/kg, s.c.).
Forelimb akinesia was assessed using the side-stepping test (Olsson et al.,
1995),where forelimbadjusting stepsarequantifiedover a total lengthof 90cm.
Forelimb asymmetry in exploratory behavior was assessed using the cylin-
der task (Bjo¨rklund et al., 2010), where the rat is placed in a glass cylinder
(20 cm in diameter) and at least 30 touches between paw and the walls are re-
corded with a digital video camera for post hoc analysis.
Lateralized sensorimotor neglect was characterized in three different tests:
the corridor task (Dowd et al., 2005), disengage task, and sensorimotor orien-
tation (Mandel et al., 1990). In the corridor task, the rats were placed inside an
opaque plastic corridor with ten pairs of food bowls, each filledwith 5–10 sugar
pellets, where the retrievals are recorded relative to the rats’ visual fields.
In the disengage task, the animals were placed on an elevated platform and
given pieces of milk chocolate (Mandel et al., 1990; Winkler et al., 2000), after
which the perioral region beneath the vibrissae on each side of the head was
repeatedly touched with the use of a wooden probe. Latency to respond was
then scored between 1 s (direct response) and 180 s (no response).
In all tests, once a stable baseline was achieved the animals were injected
with CNO (3 or 10 mg/kg, s.c.), SalB (10 mg/kg, s.c.), or a vehicle and tested
at 60 or 15 min postinjection, respectively. The researcher was blinded to
both animal group and treatment.
Abnormal Involuntary Movements
The rats were assessed for abnormal involuntary movements using a well-
characterized rating scale through rater-blinded assessment in empty trans-
parent cages (Lundblad et al., 2002). After habituation for 10 min, animals
were injected with CNO (3 mg/kg, s.c.) or ST-1936 (20 mg/kg, i.p). The animals
were scored for a total of 2 hr postinjection, with each animal being scored
every 20 min. Animals were scored for limb, axial, and orolingual abnormal
involuntary movements as well as general locomotion.
In Vivo Electrochemistry
In vivo chronoamperometry was performed using FAST-16 mk II hardware
coupled to nafion-coated carbon fiber electrodes (B 30 mm, L 150 mm) accord-
ing to (Hoffman and Gerhardt, 1998). Local application of CNO and KCl
was made by pulse pressure ejection from glass capillaries mounted 50–
100 mm from the electrode tip.
Laser-Scanning Confocal Microscopy
All LSM (laser-scanning confocal microscopy) was conducted using a Leica
SP8 setup where images were captured using a HyD detector and always
with the lasers activated in sequential mode using solid-state lasers at wave-
lengths of 405, 488, 552, and 650 nm (a pinhole of 1 AU).
Statistics
Statistical tests were performed in SPSS version 23 and include Bonferroni
corrected paired Student’s t test and one-way ANOVA or two-way mixed-
model repeated-measures ANOVA when three or more groups/states/time
points are compared, followed by Levene’s homogeneity test. The locus of ef-
fect was probed using either Dunnett’s T3 or Tukey’s least significant differ-
ence test as appropriate based on the outcome of the Levene’s test. Nonpara-
metric data were analyzed using Kruskal-Wallis test followed by Bonferroni
corrected all-pair comparison using the Mann-Whitney U test. Unless other-
wise noted, data in figures are presented as the arithmetic mean with the SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, one table, and one movie and can be found with this article online
at http://dx.doi.org/10.1016/j.neuron.2016.04.017.
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